A consortium of investors led by Frontier Capital has funded the strategic merger of 

, creating an organization designed to accelerate clinical trial enrollment from beginning to end.  The company will be led by J. Tobin Geatz, President and CEO, and Jeffrey Reiniche, CFO. 

"This novel business combination will allow sponsors and CROs to bundle the two most important services in a trial: world class sites and patient recruiting," noted Geatz.  "We will have more than 120 Principal Investigators and 80 study coordinators, who together with Inclinix's 75+ global Clinical Enrollment Managers, provide our customers rapid enrollment locally and worldwide," he continued.  

The company will operate in the short term as two divisions. 